- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11. | VIVOS INC - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11. | Vivos Inc. Issues Shareholder Update Letter | 129 | GlobeNewswire (Europe) | Kennewick, WA, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) - The Company continues to prioritize securing FDA Investigational Device Exemption (IDE) approval to initiate human clinical... ► Artikel lesen | |
| 29.10. | Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics | 152 | GlobeNewswire (Europe) | Kennewick, WA, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) today announced enhanced cooperation with Exubrion Therapeutics to advance the use of targeted radioactive isotope technology... ► Artikel lesen | |
| VIVOS Aktie jetzt für 0€ handeln | |||||
| 27.10. | Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., to Support IDE Submission for RadioGel | 1 | GlobeNewswire (USA) | ||
| 29.09. | Vivos Inc.: Vivos Inc Board Authorizes Vivos Inc to Establish a Corporate Entity in India | 2 | GlobeNewswire (USA) | ||
| 29.09. | Vivos Inc.: Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India | 118 | GlobeNewswire (Europe) | Kennewick, WA, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) The Vivos Board granted authorization to form a wholly owned corporate subsidiary in India. Vivos Inc filed for the name... ► Artikel lesen | |
| 18.09. | VIVOS INC - 8-K, Current Report | 2 | SEC Filings | ||
| 08.09. | Vivos Inc. Demonstrates Precision in Precision Radionuclide Therapy | 93 | GlobeNewswire (Europe) | Kennewick, WA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) announced new data demonstrating the exceptional precision of its proprietary Precision Radionuclide Therapy (RadioGel® for... ► Artikel lesen | |
| 03.09. | Vivos Inc.: Vivos Inc Files Critical Patent For Hydrogel Electron Beam Sterilization | 1 | GlobeNewswire (USA) | ||
| 14.08. | Vivos Inc.: Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Declined By FDA | 156 | GlobeNewswire (Europe) | Kennewick, WA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) Following the 30-day review period, the FDA declined approval of the Radiogel® IDE submission. We are now focused on addressing... ► Artikel lesen | |
| 13.08. | VIVOS INC - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 14.07. | Vivos Inc. Submitted the Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Clinic | 4 | GlobeNewswire (USA) | ||
| 15.04. | Vivos Inc. Reports Continued Progress in India Human Clinical Trial for RadioGel Precision Radionuclide Therapy | 298 | GlobeNewswire (Europe) | Kennewick, WA, April 15, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to share new developments in its ongoing human clinical trial in India for RadioGel® Precision Radionuclide Therapy... ► Artikel lesen | |
| 26.12.24 | Vivos Inc.'s IsoPet Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide | 410 | GlobeNewswire (Europe) | Richland, WA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to announce the significant achievements of its IsoPet® Animal Cancer Division, setting new milestones in veterinary... ► Artikel lesen | |
| 23.12.24 | Vivos Inc. Announces Launch of Groundbreaking RadioGel Precision Radionuclide Therapy Human Clinical Trial | 289 | GlobeNewswire (Europe) | Richland, WA, Dec. 23, 2024 (GLOBE NEWSWIRE) -- - Vivos Inc. (OTCQB: RDGL) proudly announces the initiation of its first human clinical trial for RadioGel® Precision Radionuclide Therapy in India.... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 43,510 | +1,92 % | EQS-PVR: Siemens Healthineers AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Siemens Healthineers AG
Siemens Healthineers AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
01.12.2025 /... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,040 | +0,08 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 35,790 | +1,79 % | IPO Stock Of The Week: Health Care Leader BrightSpring Falls Back Into Buying Range | ||
| PROCEPT BIOROBOTICS | 35,860 | +1,21 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| FRESENIUS | 47,720 | -0,60 % | Fresenius-Aktie: Kaufen! | Die Aktie des Gesundheitskonzerns Fresenius hat sich in den zurückliegenden Wochen doch wieder spürbar von den Mehrjahreshochs Ende Oktober entfernt. An den mittel- bis langfristigen Aussichten für... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 19,550 | +0,77 % | Alignment Healthcare Reports Third Quarter 2025 Results, Surpasses High-End of Guidance Across All Key Metrics | Reports Q3 revenue of $993.7 million, up 43.5% year-over-yearBeats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit... ► Artikel lesen | |
| PROGYNY | 24,020 | -0,54 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| GENEDX | 158,96 | -1,85 % | Cathie Wood's ARK sells Iridium, buys GeneDx and WeRide stock | ||
| BETA BIONICS | 29,380 | -2,07 % | Beta Bionics, Inc.: Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| NUTEX HEALTH | 160,95 | +2,65 % | Nutex Health extends share repurchase plan | ||
| GERRESHEIMER | 25,860 | -1,52 % | Gerresheimer vor Abstieg - Newcomer vor SDAX-Debüt? | Die nächste Indexüberprüfung am deutschen Aktienmarkt steht an. Die Entscheidung wird die Deutsche Börse heute nach Börsenschluss bekanntgeben. Nach mehreren Gewinnwarnungen und einem massiven Kursverfall... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 9,310 | +1,92 % | Aveanna Healthcare stock price target raised to $13 by Raymond James | ||
| CARL ZEISS MEDITEC | 43,440 | +0,32 % | EQS-PVR: Carl Zeiss Meditec AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Carl Zeiss Meditec AG
Carl Zeiss Meditec AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the... ► Artikel lesen | |
| CERIBELL | 19,720 | +2,98 % | Ceribell Reports Third Quarter 2025 Financial Results | SUNNYVALE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with... ► Artikel lesen | |
| GOODRX | 2,710 | -1,45 % | HIMS vs. GDRX: Which Consumer Health Stock Offers Greater Upside? |
Das Unternehmen VIVOS INC kann der Branche Gesundheitswesen zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIVOS INC finden Sie auf Wallstreet Online.